Biocryst Pharmaceuticals (BCRX) Return on Invested Capital (2023 - 2026)

Biocryst Pharmaceuticals' Return on Invested Capital history runs 4 years deep, the most recent figure standing at 0.3% for Q1 2026.

• Quarterly Return on Invested Capital fell 32.0% year-over-year to 0.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.3% (down 32.0% YoY) and the FY2025 annual result came in at 1.0%, up 101.0% from the prior year.
• Return on Invested Capital was 0.3% for Q1 2026 at Biocryst Pharmaceuticals, down from 0.24% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.24% in Q4 2025 and bottomed at 0.49% in Q1 2023.
• A 4-year average of 0.14% and a median of 0.06% in 2024 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2024 — Return on Invested Capital soared 38 bps — and 2026, when it plunged 32 bps.
• Biocryst Pharmaceuticals' Return on Invested Capital stood at 0.29% in 2023, then jumped by 99 bps to 0.0% in 2024, then jumped by 14636 bps to 0.24% in 2025, then sank by 227 bps to 0.3% in 2026.
• Business Quant data shows BCRX's Return on Invested Capital at 0.3% in Q1 2026, 0.24% in Q4 2025, and 0.07% in Q3 2025.